Neurodegenerative Disease News and Research

RSS

Allergies appear to reduce glioma risk

The more allergies one has, the lower the risk of developing low- and high-grade glioma, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Feb 2011

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Retired San Francisco real estate developer Douglas Rosenberg says he has a new job - helping to find a cure for Alzheimer's disease. Through the Ellen and Douglas Rosenberg Foundation, the venture philanthropist is betting at least $3.5 million that Buck faculty Dale Bredesen, MD has the correct take on how to thwart the memory robbing disease that affects over 5 million Americans.

31 Jan 2011

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

The University of Massachusetts Medical School and Lundbeck Inc. today announced a research collaboration aimed at further development of a targeted therapy to slow or halt the progression of Huntington's disease.

29 Jan 2011

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Research from the University of California, San Diego School of Medicine provides new clues for the compulsive behavior and cognitive defects associated with a rare childhood neurological disease called Lesch-Nyhan Disease.

29 Jan 2011

Misaligned research, medical challenges and harsh economics thwart efforts against Alzheimer's disease

Misaligned research, medical challenges and harsh economics are thwarting efforts to slow the destructive course of Alzheimer's disease in the United States, according to a trio of nationally regarded Alzheimer's researchers writing a "Perspective" in Jan. 27 issue of the journal Neuron.

28 Jan 2011

UMMS, Lundbeck enter research collaboration to develop targeted therapy for HD

The University of Massachusetts Medical School and Lundbeck today announced a research collaboration aimed at further development of a targeted therapy to slow or halt the progression of Huntington's disease.

28 Jan 2011

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

AndroScience Corp., based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

25 Jan 2011

Researchers demystify death of brain cells in Parkinson's patients

Just 5 percent of Parkinson's disease cases can be explained by genetic mutation, while the rest have no known cause. But a new discovery by researchers at The University of Texas Health Science Center San Antonio may begin to explain why the vast majority of Parkinson's patients develop the progressive neurodegenerative disease.

10 Jan 2011

Mutated TDP-43 can cause neurons to die: Study

Lou Gehrig's disease, or amyotrophic lateral sclerosis, and frontotemporal lobar degeneration are characterized by protein clumps in brain and spinal-cord cells that include an RNA-binding protein called TDP-43. This protein is the major building block of the lesions formed by these clumps.

6 Jan 2011

Prions responsible for BSE can survive in new host environment

Scientists from the Florida campus of The Scripps Research Institute have shown that prions, bits of infectious protein that can cause fatal neurodegenerative disease such as bovine spongiform encephalopathy or "mad cow disease," have the ability to adapt to survive in a new host environment.

17 Dec 2010

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).

17 Dec 2010

Researchers discover new molecular mechanism of Alzheimer's disease through protein interaction

Through a complex analysis of protein interactions, researchers from IRB Barcelona and the Joint Programme IRB-BSC have discovered new molecular mechanisms that may be involved in the development of Alzheimer's disease.

17 Dec 2010

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Repligen Corporation today announced that the Company has received $1,400,000 in research funding from the Muscular Dystrophy Association ("MDA") to support the ongoing development of RG3039 for Spinal Muscular Atrophy ("SMA"). RG3039, our lead compound, is an inhibitor of an RNA processing enzyme which targets increased production of SMN, a protein of deficient levels in patients with SMA.

15 Dec 2010

New molecular tools show promise for cleansing brain of amyloid plaques

New molecular tools developed at the University of Michigan show promise for "cleansing" the brain of amyloid plaques, implicated in Alzheimer's disease.

10 Dec 2010

VCP gene causes some instances of familial ALS: Researchers

Using a new gene sequencing method, a team of researchers led by scientists from Johns Hopkins and the National Institutes of Health has discovered a gene that appears to cause some instances of familial amyotrophic lateral sclerosis. The finding could lead to novel ways to treat the more common form of this fatal neurodegenerative disease, which kills the vast majority of the nearly 6,000 Americans diagnosed with ALS every year.

10 Dec 2010

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Investigators at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that shows promise in protecting brain cells against nerve-degenerative diseases such as Parkinson's, Alzheimer's and Huntington's, which afflict millions.

8 Dec 2010

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.

4 Dec 2010

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

KineMed Inc. presents data on the new use of cerebrospinal fluid biomarkers of microtubule-mediated neuronal transport for the monitoring of disease progression and the advancement of therapeutic interventions in Parkinson's disease, a debilitating neurological condition with considerable unmet need for new treatments.

1 Dec 2010

Breakthrough with mutant gene that causes familial ALS

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that eventually destroys most motor neurons, causing muscle weakness and atrophy throughout the body. There is no cure and the current treatment has only a moderate effect on the march of the disease, which typically kills within three to five years. This week in PNAS, a team of Brandeis scientists reports an innovative approach to treating the most common form of familial ALS, commonly known as Lou Gehrig's disease.

23 Nov 2010

Exhausted neurons die prematurely and trigger disease symptoms

We all know that living a stressful lifestyle can take its toll, making us age faster and making us more susceptible to the cold going around the office.

11 Nov 2010

Neurodegenerative Disease News and Research

Allergies appear to reduce glioma risk

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Misaligned research, medical challenges and harsh economics thwart efforts against Alzheimer's disease

UMMS, Lundbeck enter research collaboration to develop targeted therapy for HD

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

Researchers demystify death of brain cells in Parkinson's patients

Mutated TDP-43 can cause neurons to die: Study

Prions responsible for BSE can survive in new host environment

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

Researchers discover new molecular mechanism of Alzheimer's disease through protein interaction

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

New molecular tools show promise for cleansing brain of amyloid plaques

VCP gene causes some instances of familial ALS: Researchers

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

Breakthrough with mutant gene that causes familial ALS

Exhausted neurons die prematurely and trigger disease symptoms

Aneuro: A Year of Neuroscience in Review eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News